GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytoDyn Inc (OTCPK:CYDY) » Definitions » Cyclically Adjusted FCF per Share

CytoDyn (CytoDyn) Cyclically Adjusted FCF per Share : $-0.19 (As of Feb. 2024)


View and export this data going back to 2005. Start your Free Trial

What is CytoDyn Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

CytoDyn's adjusted free cash flow per share for the three months ended in Feb. 2024 was $-0.002. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-0.19 for the trailing ten years ended in Feb. 2024.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -3.40% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -4.00% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was -7.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of CytoDyn was -3.40% per year. The lowest was -11.50% per year. And the median was -7.55% per year.

As of today (2024-06-06), CytoDyn's current stock price is $0.1485. CytoDyn's Cyclically Adjusted FCF per Share for the quarter that ended in Feb. 2024 was $-0.19. CytoDyn's Cyclically Adjusted Price-to-FCF of today is .


CytoDyn Cyclically Adjusted FCF per Share Historical Data

The historical data trend for CytoDyn's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytoDyn Cyclically Adjusted FCF per Share Chart

CytoDyn Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.19 -0.19 -0.22 -0.22 -0.21

CytoDyn Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.21 -0.21 -0.20 -0.20 -0.19

Competitive Comparison of CytoDyn's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, CytoDyn's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CytoDyn's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CytoDyn's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where CytoDyn's Cyclically Adjusted Price-to-FCF falls into.



CytoDyn Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, CytoDyn's adjusted Free Cash Flow per Share data for the three months ended in Feb. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Feb. 2024 (Change)*Current CPI (Feb. 2024)
=-0.002/130.9299*130.9299
=-0.002

Current CPI (Feb. 2024) = 130.9299.

CytoDyn Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201405 -0.031 100.373 -0.040
201408 -0.046 100.352 -0.060
201411 -0.048 99.635 -0.063
201502 -0.042 99.032 -0.056
201505 -0.068 100.333 -0.089
201508 -0.073 100.548 -0.095
201511 -0.039 100.135 -0.051
201602 -0.105 100.040 -0.137
201605 -0.043 101.355 -0.056
201608 -0.050 101.617 -0.064
201611 -0.033 101.829 -0.042
201702 -0.062 102.779 -0.079
201705 -0.048 103.256 -0.061
201708 -0.046 103.587 -0.058
201711 -0.037 104.072 -0.047
201802 -0.056 105.052 -0.070
201805 -0.033 106.148 -0.041
201808 -0.041 106.383 -0.050
201811 -0.066 106.338 -0.081
201902 -0.050 106.649 -0.061
201905 -0.030 108.048 -0.036
201908 -0.042 108.245 -0.051
201911 -0.017 108.519 -0.021
202002 -0.041 109.139 -0.049
202005 -0.059 108.175 -0.071
202008 -0.074 109.662 -0.088
202011 -0.035 109.793 -0.042
202102 -0.041 110.968 -0.048
202105 -0.058 113.576 -0.067
202108 -0.050 115.421 -0.057
202111 -0.044 117.269 -0.049
202202 -0.016 119.703 -0.018
202205 -0.008 123.323 -0.008
202208 -0.014 124.958 -0.015
202211 -0.005 125.607 -0.005
202302 -0.007 126.928 -0.007
202305 -0.004 128.314 -0.004
202308 -0.005 129.538 -0.005
202311 -0.003 129.548 -0.003
202402 -0.002 130.930 -0.002

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


CytoDyn  (OTCPK:CYDY) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


CytoDyn Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of CytoDyn's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


CytoDyn (CytoDyn) Business Description

Industry
Traded in Other Exchanges
Address
1111 Main Street, Suite 660, Vancouver, WA, USA, 98660
CytoDyn Inc is a US-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The lead product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.
Executives
Tyler Blok officer: EVP of Legal Affairs 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Stephen M Simes director
Ryan Dunlap director 310 N. STATE STREET, SUITE 208, LAKE OSWEGO OR 97034
Arvin Cyrus Arman officer: President 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Karen J Brunke director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Tanya Durkee Urbach director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Lishomwa C Ndhlovu director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Harish Seethamraju director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Alan P Timmins director 1111 MAIN STREET, SUITE 600, VANCOUVER WA 98660
Gordon A Gardiner director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Samir Rashmikant Patel director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Antonio Migliarese officer: Chief Financial Officer 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Chris P Recknor officer: Chief Operating Officer 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Michael D. Mulholland officer: CFO, Treasurer and Secretary 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Jordan G Naydenov director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660

CytoDyn (CytoDyn) Headlines

From GuruFocus

CytoDyn Announces President Takes Medical Leave of Absence

By GlobeNewswire GlobeNewswire 05-24-2023